Single dose mizoribine treatment for RA: Clinical study from patient with complications and/or drug-refractory stage

DOI
  • Kikuchi Hiraku
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Sakai Hospital Kinki University School of Medicine
  • Hara Fumihiko
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Sakai Hospital Kinki University School of Medicine
  • Shimada Wataru
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Sakai Hospital Kinki University School of Medicine
  • Saito Masakatsu
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Sakai Hospital Kinki University School of Medicine
  • Ito Yasunori
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Sakai Hospital Kinki University School of Medicine
  • Tsujimoto Harutoshi
    Mizoribine Research Meeting of the Kinki University School of Medicine Rehabilitation, Sakai Hospital Kinki University School of Medicine
  • Soen Satoshi
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Nara Hospital Kinki University School of Medicine
  • Nonaka Tohgo
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Kinki University School of Medicine
  • Akagi Masao
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Orthopaedic Surgery, Kinki University School of Medicine
  • Funauchi Masanori
    Mizoribine Research Meeting of the Kinki University School of Medicine Department of Internal Medicine, Kinki University School of Medicine

Bibliographic Information

Other Title
  • 関節リウマチ治療におけるミゾリビン単回投与 ―各種抗リウマチ薬が使用し難い症例あるいは効果不十分な症例等における検討―

Search this article

Description

We performed single dose mizoribine (MZR: immunosuppressive drug) treatment with high daily concentration for patients with rheumatoid arthritis (RA). This clinical trial was performed on 18 RA patients (4 Male, 14 Female. Age 33-81. Duration 1-15 years. StageI: 5, III: 1, IV: 12. Class2: 13, 3: 4. Disease Activity Score: DAS 28＝5.0＋/－1.3) with complications and/or some drugs refractory stage in Kinki University School of Medicine over six months. Finally, five of the 18 RA patients improved in not only clinical data on the DAS 28＝3.7＋/－0.9 and personal comfortableness but also decreased steroid dose and other drugs. Another five RA patients continued the trial but remained unchanged (DAS 28＝4.3＋/－1.0), and eight RA patients discontinued the trial: three were unchanged (DAS 28＝5.1＋/－0.7), three were personal dropout (DAS 28＝6.1＋/－1.0), one was side effect (oral erosion on 3 months later) and one was worse. Five of the eight dropout RA patients used biologics after this trail. The effectiveness of single dose mizoribin treatment for RA patients was demonstrated one of the effectiveness in this study.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top